High-load oral film formulation with improved bioavailability

Abstract

The present application discloses an oral film dosage form comprising: i. suspended maropitant or a salt thereof; ii. an aqueous phase consisting of water and at least one surfactant; iii. at least one viscosity-increasing agent / suspending agent; and iv. at least one solubilizing agent.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 396,956, filed August 10, 2022, which is incorporated herein by reference in its entirety.

[0002] The present disclosure relates to oral film dosage formulations and processes for preparing oral film dosage forms, and more particularly to the preparation of oral film dosage forms suitable for high active-loading films for both human and veterinary applications that exhibit improved bioavailability. [Background technology]

[0003] It is often desirable to administer pharmaceutical ingredients using oral film dosage forms. Oral film dosage forms have several advantages when compared with tablets and capsules. Many people have difficulty swallowing tablets and capsules and risk choking while attempting to swallow solid oral dosage forms, but film dosage forms can be self-administered without difficulty. Similarly, administering drugs to animals, such as companion animals, through various dosage forms often presents unique challenges, particularly the need for dosing accuracy. Animals may reject some of the tablets, some of which often need to be broken into several small pieces, amplifying the inaccuracy of dosing.

[0004] While administering drugs in oral film dosage forms may be desirable, designing oral dosage forms that provide the desired absorption profile remains a challenge. Oral film dosage forms have the potential to enhance the absorption rate of drugs or active pharmaceutical ingredients (APIs). Despite the desirable benefits of oral film dosage forms, the application of suitable oral film dosage forms has thus far been limited, in part, due to the limited API content of oral films. The low API content of oral films stems from several inherent factors for oral films, such as size limitations dictated not only by pharmacokinetics but also by the size of the human or animal mouth. The mechanical properties of oral films also limit the API content required to achieve adequate plasticity parameters for the oral film packaging process. These unfortunate limitations of oral films have left the capabilities of oral film dosage forms relatively untapped, as evidenced by the limited number of approved drugs with oral dosage forms.

[0005] The use of maropitant to treat vomiting and associated distress is not new in the art. WO 2005 / 082416 describes the development of a pharmaceutical formulation of maropitant citrate, sulfobutyl ether β-cyclodextrin, and metacresol. The administration method in this case is a dermal injection, which may cause pain and adverse reactions in animal subjects. EP 3173071 A1 relates to a pharmaceutical composition containing maropitant, a method for preparing the composition, the use of the composition as a medicament, and the use of the composition in the treatment of vomiting in mammals, particularly cats and dogs. The administration method in this case improves on the injection method but does not consider other administration alternatives, such as oral films. CN 110577522 A relates to a new crystalline form of maropitant citrate and a method for preparing the same, but does not mention the use of a film as an administration method.

[0006] Several methods exist in the art for orally administering compositions to treat vomiting and related distress in animals, e.g., CA2965524, in which the oral form is a soft, chewable composition that does not bypass the hepatic circulation as much as oral films and generally employs different composition technologies and biological systems.

[0007] Veterinary oral films also exist in the art, e.g., US20040115253, US20060121096, US20140286876, US20160166511, etc. There is a need for effective, high-load animal health films with improved bioavailability.

[0008] Oral film technology can provide an alternative dosage form to injections and tablets, and can provide convenience to patients or pet owners by providing medications that can be administered more easily without the need for the patient or pet owner to visit a clinic, undergo pain, or embed the dosage form in food. There is also a need to improve the bioavailability of high concentrations of active agents in treatments, and to improve compliance with treatments by improving product administration and acceptability.

[0009] These and other inefficiencies and opportunities for improvement are addressed and / or at least partially overcome by the systems, assemblies and methods of the present disclosure. Summary of the Invention

[0010] Generally, oral films include a solubilized API in a solubilizer, a permeation co-enhancer, a suspended API, a surfactant system, a suspending agent / viscosity enhancer, a plasticizer, flavors, taste masking agents, and a polymeric film matrix.

[0011] According to some embodiments of the present disclosure, the oral film dosage form includes at least one API in a dual system: the API in solubilizer(s) and the API suspended in a polymeric mucoadhesive film matrix.

[0012] In certain aspects of the present disclosure, the disclosed formulations and excipients are specifically adapted for human use.

[0013] In certain aspects of the present disclosure, the disclosed formulations and excipients are specifically adapted for use in animals.

[0014] These and other features, advantages, and objects of various embodiments will become better understood with reference to the following specification and claims. [Brief explanation of the drawings]

[0015] [Figure 1] Figure 1 shows the permeation test of three maropitant oral films across the porcine buccal mucosa. A Franz cell apparatus was used for the permeation test, with purified water as the donor medium and 30% hydroxypropyl-β-cyclodextrin in purified water as the receiver medium. The maropitant concentration (µg / cm²) in the receiver medium demonstrates the superiority of the oral film (Lot 164-24-2), in which maropitant is dissolved under acidic conditions. This is followed by the oral film (Lot 164-28-3B), in which maropitant is partially dissolved in oleic acid and benzyl alcohol. Finally, the profile of the oral film (Lot 164-44), in which maropitant is largely suspended, is shown. It is clear that API solubility enhances permeation. [Figure 2] A similar permeation study as in Figure 1 is shown, comparing the effect of a permeation co-enhancer (glycerol in lot 164-28-3A vs. PEG300 in lot 164-28-3B) on the permeation of maropitant oral films containing the two solubilizers oleic acid and benzyl alcohol. [Figure 3] Similar permeation studies as in Figure 1 are shown, showing improved permeation when solubilizer oleic acid from lot 164-5E was used for the first 5 hours compared to benzyl acetate from lot 164-25-1 and benzyl alcohol from lot 164-15-2. [Figure 4]The same permeation studies as in Figure 1 are shown. Figure 4 shows the improvement in maropitant permeation in lot 164-28-3A when a water-soluble solubilizer (benzyl alcohol) was added and the amount of surfactants Tween 20 and Labrafil was increased to maropitant oral film (lot 164-28-6A), which already uses oleic acid as a solubilizer. Figure 4 shows the improvement in maropitant permeation and the shortening of lag time in lot 164-28-3B when the permeation co-enhancer glycerol (lot 164-28-3A) was replaced with PEG 300. Figure 4 shows the improvement in maropitant permeation and the shortening of lag time in lot 164-28-6B when the permeation co-enhancer glycerol (lot 164-28-6A) was replaced with propylene glycol. Optimizing lot 164-28-6A by adding benzyl alcohol to further supplement tween and labrafil yields lot 164-28-3A, which exhibits a similar permeation profile to lot 164-28-6B, which only has the permeation co-enhancer switched from glycerol (lot 164-28-6A) to propylene glycerol (lot 164-28-6A). Thus, this improvement of lot 164-28-3A to lot 164-28-3B produces a better permeation profile than lot 164-28-6B. [Figure 5] The permeation studies are similar to those shown in Figure 1. Figure 5 shows the improvement in maropitant permeability for lot 164-5E with increasing amounts of solubilizer (oleic acid) compared to lot 164-28-6A. DETAILED DESCRIPTION OF THE INVENTION

[0016] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0017] It is to be understood that the present disclosure is not limited to particular embodiments described, as such may, of course, vary, and that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0018] As used herein, the terms "a," "an," or "the" are used to include one or more unless the context clearly dictates otherwise. The term "or" is used to refer to an inclusive "or" unless otherwise indicated. Furthermore, expressions or terms used herein and not otherwise defined should be understood to be for descriptive purposes only and not limiting. The use of section headings is for ease of reading the document and should not be construed as limiting; information associated with a section heading may be located within that particular section or outside of that section. Furthermore, all publications, patents, and patent documents referenced herein are incorporated herein by reference in their entirety, as if individually incorporated by reference. In the event of a conflict in usage between this specification and those documents so incorporated by reference, the usage in the incorporated references should be considered supplementary to the usage in this document; in the event of a conflict, the usage in this document will control.

[0019] Values ​​expressed in range format should be interpreted flexibly to include not only the numerical values ​​explicitly stated as the limits of the range, but also all individual numerical values ​​or subranges contained within that range, as if each numerical value and subrange were explicitly stated. For example, the range "about 0.1% to about 5%" or "about 0.1% to 5%" should be interpreted to include not only about 0.1% to about 5%, but also individual values ​​(e.g., 1%, 2%, 3%, and 4%) and subranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the stated range.

[0020] As used herein, the term "about" allows for a degree of variation in values ​​or ranges, for example, within 10%, within 5%, or within 1% of a stated value or the limits of a stated range. When a range or list of continuous values ​​is given, any value within that range or between the specified continuous values ​​is also disclosed, unless otherwise specified.

[0021] As used herein, the term "substantially" refers to a majority or majority of a portion, such as at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.

[0022] Film systems embody a technological field with significant advantages in the area of ​​administering various active agents to individuals or subjects in need thereof. The present disclosure relates to oral films, also referred to in the art as films and film strips, and methods for forming film products containing at least one active agent, including film strips, sheets, discs, wafers, and the like, in any shape, such as rectangular, square, or other desired shape. Specifically, the present disclosure provides films and methods for forming films. Terms such as "orally dissolving film," "orally dissolving film," "orally disintegrating film," OSF, "orally dissolving film," "OCF," "orally chewable film," "ODF," "orally dissolving film," "OTF," "oral thin film," "oral strip," and the like refer to products used to administer a predetermined amount of active ingredient(s) via oral routes such as oral transmucosal absorption, sublingual delivery, or buccal delivery, and are referred to throughout as "oral film(s)."

[0023] The term "active ingredient(s)" or "API" refers primarily to active pharmaceutical ingredients, drugs, or pharmaceutical agents, but may also refer generally to any agent(s) intended to be incorporated into a finished pharmaceutical product and to provide pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or some function of the body of a subject.

[0024] A pharmaceutical composition may contain one or more active pharmaceutical ingredients. The active pharmaceutical ingredient may be a single pharmaceutical ingredient or a combination of pharmaceutical ingredients. The active pharmaceutical ingredient may be an anti-inflammatory analgesic, a steroidal anti-inflammatory agent, an antihistamine, a local anesthetic, a bactericide, a disinfectant, a vasoconstrictor, a hemostatic agent, a chemotherapeutic agent, an antibiotic, a keratolytic agent, a cauterizing agent, an antiviral agent, an antirheumatic agent, an antihypertensive agent, a bronchodilator, an anticholinergic agent, an anxiolytic agent, an antiemetic compound, a hormone, a peptide, a protein, or a vaccine. The active pharmaceutical ingredient may be a compound, a pharmaceutically acceptable salt of a drug, a prodrug, a derivative, a drug conjugate, or a drug analog. The term "prodrug" refers to a biologically inactive compound that can be metabolized in the body to produce a biologically active drug.

[0025] In some embodiments, the film may include multiple pharmaceutically active ingredients, such as ACE inhibitors, antianginals, antiarrhythmics, antiasthmatics, anticholesterols, analgesics, anesthetics, anticonvulsants, antidepressants, antidiabetics, antidiarrheals, detoxifiers, antihistamines, antihypertensives, anti-inflammatory agents, antilipids, antimanic agents, antinausea agents, antistroke agents, antithyroid agents, amphetamines, antineoplastics, antivirals, antiacne agents, alkaloids, amino acid preparations, antitussives, antiuricemics, antivirals, anabolic preparations, systemic and Non-systemic anti-infectives, anti-tumor agents, anti-Parkinson's agents, anti-rheumatic agents, appetite stimulants, blood regulators, bone metabolism regulators, cardiovascular agents, central nervous system stimulants, cholinesterase inhibitors, contraceptives, decongestants, dietary supplements, dopamine receptor agonists, endometriosis management agents, enzymes, erectile dysfunction medications, infertility treatment agents, gastrointestinal agents, homeopathic remedies, hormones, hypercalcemia and hypocalcemia management agents, immunomodulators, immunosuppressants, migraine medications, Motion sickness medication, muscle relaxant, obesity management agent, osteoporosis medication, uterotonics, parasympatholytics, parasympathomimetics, prostaglandins, psychiatric medication, respiratory medication, sedatives, smoking cessation aids, sympatholytics, tremor medication, urinary tract medication, vasodilators, laxatives, antacids, ion exchange resins, antipyretics, appetite suppressants, expectorants, anxiolytics, antiulcer drugs, anti-inflammatory substances, coronary artery dilators, cerebral dilators, peripheral vasodilators, psychotropic drugs, hallucinogens, stimulants, antihypertensives, vascular The agent may be a constrictor, antimigraine medication, antibiotic, tranquilizer, antipsychotic, antineoplastic, anticoagulant, antithrombotic, hypnotic, antiemetic, antinausea, anticonvulsant, neuromuscular, hyperglycemic and hypoglycemic, thyroid and antithyroid, diuretic, anticonvulsant, uterine relaxant, antiobesity agent, erythropoietic, antiasthmatic, cough suppressant, mucolytic, DNA and genetic modification agent, diagnostic agent, contrast agent, dye or tracer, and combinations thereof.

[0026] The film products of the present disclosure include an active ingredient selected from pharmaceuticals, bioactive agents, cosmetics, and combinations thereof. The active ingredient can be present in any desired amount effective for the intended treatment. The ability to include a high active ingredient loading is particularly desirable and an advantage of the present disclosure. Bioactive agents for oral films are substances that have a specific biological effect when administered orally and are often used to achieve therapeutic results in pets or humans. These agents include pharmaceuticals, vitamins, minerals, dietary supplements, enzymes, probiotics, hormones, and the like. When incorporated into oral film formulations, they target conditions such as pain, inflammation, infection, or support general health. Considerations include stability, bioavailability, and controlled release to provide a convenient and effective administration method while optimizing the efficacy of the agent.

[0027] The various additives that can be incorporated into the film can provide a variety of different functions. Examples of classes of additives include excipients, lubricants, buffers, stabilizers, foaming agents, pigments, colorants, fillers, bulking agents, sweeteners, flavorings, fragrances, release agents, adjuvants, plasticizers, glidants, mold release agents, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, anti-adherents, acidulants, softeners, resins, demulcents, solvents, surfactants, emulsifiers, elastomers, and mixtures thereof. These additives may be added together with the active ingredient.

[0028] The term "matrix" or "film matrix" refers to a polymer component or mixture of polymers that creates a film-forming matrix that supports the API within the oral film dosage form.

[0029] The term "amorphous" refers to the non-crystalline form of a solid, lacking a regular crystalline organization of atoms. The amorphous content (amorphism) of a solid can be accurately and precisely assessed using a number of well-established methods, including isothermal calorimetry, powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), continuous relative humidity perfusion, microcalorimetry (cRHp), and dynamic vapor sorption (DVS). In this document, the term amorphous also refers to an active agent exhibiting 30% or more than 30%, more preferably more than 50% amorphous material. The term "stable" refers to a product that shows no change in degradation profile or remains within established specifications and recovery when the product is exposed to normal stability conditions (e.g., 25°C / 60% RH and 40°C / 75% RH) for extended periods of time, while also exhibiting no chemical degradation. The term "stable" can also refer to mechanical stability; for example, if the product recrystallizes, changes in flexibility and other mechanical properties occur. The term "stable" can also refer to chemical stability, which refers to a product that exhibits analytical and impurity profile changes that remain within the specified specifications, although exhibiting chemical degradation within the specified specifications, when the product is exposed to normal stability conditions (e.g., 24 months at 25°C / 60% RH and 6 months at 40°C / 75% RH).

[0030] The term "nonsolubilized" refers to a crystalline, amorphous, or partially amorphous active agent(s) suspended (insoluble) in another substance, a solvent, forming a homogeneous solution. The stability of an API can be enhanced in the finished film product by using the API as a partially / nonsolubilized dispersion. Solubilized APIs, especially crystalline APIs, may recrystallize over time during storage and under preservation conditions, potentially adversely affecting the overall bioavailability of the product. The selection of a partially / nonsolubilized API can also be used to control the dissolution behavior and release of the API from the film administration for systemic uptake in patients. API uptake and absorption are governed by drug solubility and bioavailability; therefore, controlling its crystallinity and particle size can influence the bioavailability of the API in the human or animal body.

[0031] An average particle diameter (D50) equal to or smaller than 250 μm refers to the size distribution of solid particles uniformly distributed within the matrix film, which may be small enough to avoid either a rough texture or an unpleasant mouthfeel experience upon oral ingestion.

[0032] The term "suspended" (and variations thereof) refers to a dispersion of solid materials (e.g., particles or powders) in a bulk liquid medium, where the solid materials are not completely dissolved at the molecular level and will eventually settle out of the liquid without agitation, or are a mixture of sufficient viscosity. In a suspension, the suspended materials are not completely dissolved in the liquid.

[0033] The term "polymer" refers to a long molecular chain made up of many repeating units. "Film-forming polymer" refers to a polymer used in the formation and manufacture of a film matrix.

[0034] The term "water-soluble component" refers to a component that can be dissolved in water.

[0035] The term "water-insoluble ingredient" refers to an ingredient that cannot generally be dissolved in water.

[0036] The term "suspending agent" (also called "viscosity-enhancing agent") refers to a water-soluble or water-insoluble component, or combination thereof, that is used to increase the viscosity of the drug vehicle sufficiently to prevent adjacent suspended particles from coming close enough to bind to each other, thereby maintaining a stable suspension (suspended entities) through steric stabilization. Certain suspending agents / viscosity-enhancing agents also interact with the mucosa of an organism to create enhanced oral film mucoadhesion. Examples include the following and their derivatives, such as hydroxypropyl methylcellulose (HPMC) (the polymer structure combines both hydrophobic (methoxy groups) and hydrophilic substituents (hydroxypropoxy groups) and has a 2% aqueous solution viscosity of about 1298 to about 15000 millipascal seconds (mPas) (2%, 20°C)), hydroxypropyl cellulose (HPC) (2% aqueous solution viscosity is greater than about 150 mPas (2%, 25°C)), hydroxyethyl cellulose (HEC), gums such as water-soluble carboxymethyl cellulose (CMC), gellan, propylene glycol alginate, water-soluble alginates, acacia, pectin, xanthan, guar gum, carrageenan, and polysaccharides in the form of one or a mixture of water-insoluble alginic acid derivatives, water-insoluble CMC derivatives, colloidal silicon dioxide, agar, locust bean, and tragacanth. This definition also includes polyvinylpyrrolidone with a molecular weight (MW) of 1,000,000 MW and above (K value of 85 and above) with an aqueous solution viscosity of 300 mPAs (10%, 20C), as well as high molecular weight polyethylene oxide (PEO) (MW above 600,000).Excluded from the definition of the term "suspending agent / viscosity increasing agent" are one or a mixture of the following: HPMC (the polymer structure does not combine both hydrophobic and hydrophilic substituents and / or has an aqueous solution viscosity of less than 1298 mPas or more than 15000 mPas (2%, 20C)), methylcellulose (MC), microcrystalline cellulose (MCC), powdered cellulose, sodium starch glycolate, starch, polyvinylpyrrolidone-vinyl acetate copolymer, polyplasdone crospovidone, with a MW less than 1,000,000 MW and a K value less than 85 and an aqueous solution viscosity of less than 300 mPas (10%, 20C), HPC (having a 2% aqueous solution viscosity of less than 150 mPas (2%, 25C)), water-insoluble bentonite.

[0037] The term "surfactant" or "surfactant system" refers to an amphiphilic structure that has a polar hydrophilic head (ionic or nonionic) and a nonpolar hydrophobic tail. The balance between the hydrophilic and lipophilic portions of an amphiphilic molecule is referred to as the hydrophile-lipophile balance (HLB). Surfactants are used to dissipate the free surface energy of particles by reducing the interfacial tension and contact angle between the solid and the suspending vehicle, and include PEG 300 oleic acid glycerides (Labrafil® M-1944CS), PEG 300 linoleic acid glycerides (Labrafil® M-2125CS); hydroxylated lecithin; caprylocaproyl polyoxyl-8 glycerides; polyoxyethylene (4) sorbitan monooleate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene (5) sorbitan monooleate, polyoxyethylene 20 sorbitan trioleate; sorbitan esters (sorbitan fatty acid esters), such as sorbitan monolaurate, polyoxyethylene sorbitan fatty acid esters, such as polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene (4) sorbitan monolaurate. Polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monostearate, polyoxyethylene 20 sorbitan monooleate, polyoxyethylene 20 sorbitan monoisostearate, polyethylene glycol monostearate (Gelucire 48 / 16), poloxamers with a MW of 2200 to a maximum of 14,600 and a viscosity of 700-3100 mPAs (as a melt at 77°C), but excluding surfactants with an HLB less than 7, such as propylene glycol monocaprylate type I, propylene glycol monocaprylate type II, propylene glycol monolaurate, sorbitan monoisostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, sorbitan tristearate, and glyceryl monooleate.

[0038] The term "co-surfactant" refers to a chemical added to a surfactant to improve its performance: thus, a second surfactant used in combination with the primary surfactant. Co-surfactants are typically alcohols, C4 to C10 amines, or molecules with a polar hydrophilic head (ionic or non-ionic) and a non-polar hydrophobic tail. Co-surfactants aid in the formation and stabilization of micelles / microemulsions.

[0039] The term "solubility enhancer" refers to an excipient used to solubilize low-solubility drugs through non-covalent interactions, allowing for enhanced dissolution and bioavailability of the drug. Non-covalent interactions include van der Waals forces, hydrogen bonding, dipole-dipole and ion-dipole interactions, with electromagnetic interactions being preferred in certain cases. In the present disclosure, solubility enhancers include one or a combination of two types of excipients: type (I) amphiphilic structures having both hydrophobic and hydrophilic components, and type (II) non-amphiphilic structures having either a predominantly hydrophilic or a predominantly hydrophobic component, or a combination thereof.Solubility enhancers are divided into two categories, the first being amphiphilic solubility enhancers type (I): A) cellulose derivatives, such as but not limited to HPMC with an aqueous solution viscosity of 500 mPas or less (NMT) (5%, 25C) and low molecular weight (MW) hydroxypropyl cellulose (HPC) (up to 95,000) with an aqueous solution viscosity of 150 mPas or less (NMT) (5%, 25C), and B) surfactant(s) with an HLB of 3-7 (category I) or HLB of 7 or more or a combination of the two categories: e.g. Examples include, but are not limited to, sodium lauryl sulfate, copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), i.e., poloxamers with a MW of up to 14,600 and a viscosity of up to 3100 mPas (77°C); PEG 300 oleic acid glycerides, PEG 300 linoleic acid glycerides; sorbitan esters (sorbitan fatty acid esters), such as: sorbitan monoisostearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, ...isostearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monoisostearate, sorb polyoxyethylene sorbitan fatty acid esters, for example: polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene (4) sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monostearate, polyoxyethylene (4) sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene 20 sorbitan monooleate, polyoxyethylene (5) sorbitan monooleate, polyoxyethylene C) Polyvinylpyrrolidone of MW up to 1,500,000 with an aqueous solution viscosity of NMT 700 mPAs (10%, 20°C), D) Polyethylene oxide (PEO) of MW up to 300,000 with an aqueous solution viscosity of NMT 1200 mPAs (5%, 25°C), and E) Cyclodextrins and their derivatives.The second category of non-amphiphilic solubility enhancers, Type (II): A) have a majority of hydrophilic components, including but not limited to glycerol, propylene glycol, and PEG, with a MW of up to 6600 and a viscosity of 390 mPas or less (NMT) (98.98°C + / - 0.3°C); B) have a majority of hydrophobic components, including but not limited to oily surfactants and oily solubility enhancers with a low hydrophilic-lipophilic balance (HLB) of less than 3, including but not limited to medium chain triglycerides (MCT), glycerol monolinoleate (Maisin CC™), soybean oil, olive oil, sorbitan trioleate, and sorbitan tristearate.

[0040] The term "solubilizer" also includes any excipient that acts as a "solubility enhancer" and solubilizes a greater proportion of the API compared to the "solubility enhancers" of the present invention. In the present disclosure, solubilizers include one or a combination of: 1) non-volatile solubilizer(s) with a more lipophilic character with a logp of less than 8, such as surfactant(s), fatty acids, oils, or other lipid-based excipients with an HLB of up to 7 (category I), non-limiting examples of which are α-linolenic acid, α-linoleic acid, oleic acid, olive oil, sesame oil, and palm oil; 2) non-volatile solubilizer(s) with a hydrophilic character with a logp of less than 5, such as, but not limited to, surfactant(s) with an HLB of 7 or more (category II), benzene derivatives such as, but not limited to, benzaldehyde, benzyl acetate, and benzyl benzoate; pH adjusters such as, but not limited to, hydrochloric acid, citric acid, sodium hydroxide, and sodium citrate; and hydrophilic surfactants such as, but not limited to, polysorbates and sodium lauryl sulfate. Non-volatile solubilizer(s) of hydrophilic character also include PEO and its derivatives, cellulose derivatives such as, but not limited to, HPMC with an aqueous viscosity of 500 mPas (2%, 25°C) or less (NMT) and HPC with a low molecular weight (MW) (up to 95,000) with an aqueous viscosity of 150 mPas (5%, 25°C) or less (NMT); 3) volatile solubilizer(s) that evaporate under normal room atmospheric temperature and pressure conditions, non-limiting examples of which include ketone derivatives such as methyl ethyl ketone and acetone, alcohols such as methanol and ethanol, and alkanes such as hexane.

[0041] The term "solubilization system" for oral films refers to a combination of ingredients or components within a film formulation that enhances the solubility and dissolution of hydrophobic or poorly water-soluble substances, such as active pharmaceutical ingredients (APIs) or bioactive agents. Solubilization systems are designed to improve the dispersibility of these substances within the film matrix and ensure their effective release and bioavailability upon oral administration of the film. For oral films for pets or humans, solubilization systems may include various excipients, surfactants, cosolvents, and other additives that interact with hydrophobic components, disrupting their structure and allowing them to more easily mix with the surrounding aqueous environment. This results in a homogeneous and stable formulation that allows for efficient absorption of the active ingredient upon administration.

[0042] The purpose of solubilization systems in oral films is to overcome the challenges of delivering poorly water-soluble compounds, which can otherwise lead to uneven distribution, reduced bioavailability, and reduced therapeutic efficacy. Using an effective solubilization system, oral films can increase the solubility and dissolution of bioactive agents, thereby optimizing absorption and ensuring consistent and reliable therapeutic results.

[0043] The term "mucoadhesive" and variations thereof generally refer to a film matrix or pharmaceutical dosage form that interacts by adhesion with the mucus covering the epithelium.

[0044] The term "antifoaming agent" refers to any substance added to prevent or suppress the formation of foam in a formulation. Generally, these agents have surfactant properties and are insoluble in the foaming medium. Commonly used antifoaming agents include, but are not limited to, certain alcohols (cetostearyl alcohol), insoluble oils (castor oil), polydimethylsiloxane and other silicone derivatives, ethers, and glycols.

[0045] The term "mucoadhesive film-forming agent" refers to a polymer that forms a film matrix, film strip, or film sheet and dissolves in an aqueous environment to provide bioadhesive properties to the mucosa. Non-limiting examples include the following polymers and their derivatives: PEO, pullulan, CMC, HPC, HPMC, HEC, ethyl cellulose (EC), polyvinyl alcohol (PVA), polymethacrylate polymers (including their derivatives). Examples of mucoadhesive materials that can be used to prepare the mucoadhesive film matrix include, but are not limited to, the following and their derivatives: poly(ethylene oxide), polyvinylpyrrolidone, poly(acrylic acid) derivatives (e.g., commercially available Carbopol®), polycarbophil, polyoxyalkylene ethers, polymethacrylates, polymethacrylate-based copolymers (e.g., commercially available Eudragit®), biodegradable polymers such as poly(D,L-lactide-co-glycolide) (e.g., commercially available Resomer®), anionic biopolymers such as hyaluronic acid or sodium carboxymethylcellulose, cationic biopolymers such as chitosan or poly(L-lysine), and other cellulose derivatives. Other mucoadhesive polymers that can be used include methyl vinyl ether maleic acid, mixed salts of sodium / calcium methyl vinyl ether maleate, methyl vinyl ether maleic anhydride, and half esters (monoethyl; monobutyl, and isopropyl esters) of methyl vinyl ether maleic anhydride copolymers (e.g., commercially available Gantrez®).

[0046] In oral films, agglomeration inhibitors are substances or ingredients added to the film formulation to prevent or minimize the formation of aggregates, or particle clusters. Aggregates form when small particles stick together and can adversely affect the quality, uniformity, and efficacy of oral films. Anti-agglomeration inhibitors help maintain desirable film properties, such as film texture, appearance, and uniform distribution of active ingredients. Examples include, but are not limited to, polyvinylpyrrolidone and hydroxypropyl methylcellulose (HPMC), whose polymer structure combines both hydrophobic (methoxy groups) and hydrophilic (hydroxypropoxy groups) substituents and has an aqueous viscosity of up to 15,000 mPas (2%, 20°C), used alone or mixed with methylcellulose (MC), which has an aqueous viscosity of up to 5,040 mPas (2%, 20°C).

[0047] The term "stabilizer" refers to molecules that prevent chemical degradation, such as D-α-tocopheryl polyethylene glycol succinate (TPGS), citric acid, vitamin E, ascorbic acid, ethylenediaminetetraacetic acid (EDTA), glutathione, L-cysteine, tocobiol, BHT (butylated hydroxytoluene), BHA (beta hydroxy acid), or combinations thereof.

[0048] The term "crystal growth inhibitor" refers to polymers that inhibit or retard crystal growth within the nucleus, examples of which include, but are not limited to, the following and their derivatives: polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC, HPC, MC, polyvinylpyrrolidone / vinyl acetate (PVP / VA), and polyvinyl acetate (PVAc).

[0049] The term "preservative" refers to an agent that extends the shelf life of food and nonfood products by slowing or preventing deterioration of flavor, odor, color, texture, appearance, nutritional value, or safety. Preservatives need not provide a lethal, irreversible action that results in the partial or complete destruction or incapacitation of microbial cells. Sanitizers, disinfectants, bactericides, sporicides, virucides, and tuberculocides provide such an irreversible mode of action and are sometimes referred to as "bactericidal" action. In contrast, preservatives may provide a reversible inhibitory or bacteriostatic effect, in that target microorganisms can resume growth once the preservative is removed. The primary differences between preservatives and disinfectants are primarily the mode of action (preservatives prevent the growth of microorganisms rather than killing them) and exposure time (preservatives act for days to months, whereas disinfectants act within minutes at most). In certain embodiments, preservatives include, but are not limited to, at least one of the following, or derivatives thereof: sodium benzoate, methylparaben, propylparaben, sodium sorbate, and the like.

[0050] As used herein, the term "high loading" can refer to a film with a high amount of API, such as a film containing more than 50 mg of API. High loading can also be described in terms of the composition of the film, such as up to 40% of the film being composed of API.

[0051] The term "bioavailability," as defined in the art, refers to the ability of a drug or other substance to be absorbed and used by the body. Bioavailability is an important factor in oral film technology. The sublingual mucosa has high membrane permeability due to its thin membrane structure and high vascularity. This rapid blood supply results in very good bioavailability. Improved systemic bioavailability is due to skipping the first-pass effect, while improved permeability is due to high blood flow and lymphatic circulation. Furthermore, the oral mucosa is a highly effective and selective route for systemic drug delivery due to its large surface area and easy application for absorption. Studies have shown that thin films can improve the initial drug effect and duration of this effect, reduce dosing frequency, and increase drug efficacy.

[0052] As used herein, the term "plasticizer" refers to a substance that creates or promotes plasticity and flexibility and reduces brittleness. Plasticizers can be advantageously used in film formulations, as needed, to appropriately modify the flexibility of the film to facilitate processing and allow the film to easily conform to the shape of the oral mucosa to which it is applied. Plasticizers can lower the glass transition temperature of the film-forming polymer (e.g., the water-soluble polymer or polymers in the film). Examples of plasticizers that can be used in the disclosed oral film dosage forms include, but are not limited to, the following and their derivatives, such as triacetin, triethyl citrate, tributyl citrate, acetyltributyl citrate, acetyltriethyl citrate, trioctyl citrate, acetyltrioctyl citrate, trihexyl citrate, sorbitol, maltitol, dibutyl sebacate, PEG 300, PEG 400, glycerin, and the like. The plasticizer(s) may be added alone or in combination in an amount up to 25% of the total mass of the film oral dosage form, for example, 0% to 25%, 1% to 20%, 2% to 15%, or 5% to 10%.

[0053] The terms "flavoring agent" or "flavoring agent" and variations thereof generally refer to concentrated preparations, with or without flavor adjuvants required in their manufacture, used to impart flavors other than salty, sweet, or sour. Flavoring agents may be classified as natural, artificial, or natural and artificial (N&A) by combining all natural and synthetic flavors, or other forms known in the art. Flavoring agents are categorized by their physical classification as solid flavoring agents and liquid flavoring agents.

[0054] The term "natural flavor" and its variations generally refer to flavors obtained from natural sources, such as spices, fruits, and vegetables. They may also be obtained from herbs, bark, roots, or similar plant materials. Natural flavors are also obtained from meat, seafood, poultry, eggs, and dairy products. Flavorings are used solely to add flavor to foods; by definition, they generally have no nutritional value.

[0055] The term "artificial flavor" and its variations generally refer to flavors that do not meet the definition of natural flavor. The chemical composition of natural and artificial flavors is usually similar, but the source material is what differs. The active ingredients of natural flavors used to impart flavor are often synthetically identified and reconstructed with reasonable precision.

[0056] The term "natural and artificial (N&A) flavors" and its variations generally refer to natural flavors combined with synthetic ingredients to enhance flavor balance and richness. These flavors are generally categorized by type and taste.

[0057] The term "liquid flavor" and its variants generally refer to flavors in a liquid phase, with or without a liquid carrier. Its texture generally depends on the solvent in which the flavor is prepared. Liquid flavors are available as both oily (e.g., essential oil) or non-oily liquids. Examples of liquid flavors include, but are not limited to, essential oils, liquid extracts, tinctures, distillates, or other forms known in the art. The term "liquid" and its variants generally refer to viscous liquids, slurries, foams, pastes, gels, etc.

[0058] Other known techniques used to mask the unpleasant taste of active agents include the addition of taste masking agents, sweeteners, and flavor enhancers (sometimes called "savor boosters").

[0059] The term "flavor enhancer" and its variants generally refer to compounds that specifically enhance a particular taste or reduce undesirable flavors without having a particularly strong taste of their own. They balance the taste components and make food / drug formulations more pleasant. Examples include, but are not limited to, maltol, ethyl maltol, monosodium glutamate, glutamic acid, glutamate salts, purine-5-ribonucleotides, inosine, guanosine, adenosine-5-monophosphates, sugars, sweeteners, carboxylic acids (e.g., citric acid, malic acid, and tartaric acid), salt (NaCl), amino acids, some amino acid derivatives (e.g., monosodium glutamate-MSG), and frequently used spices (e.g., pepper), yeast, yeast extract, dried yeast, etc., or mixtures thereof.

[0060] The term "taste masking agent" and its variants generally refer to ingredients that can mask or at least make unpleasant odors or tastes in foods or medicines more acceptable. Among the many tastes that must be masked in medicines, bitterness is the most frequently encountered, yet difficult to completely mask. Examples of bitterness masking agents include, but are not limited to, licorice, coffee, chocolate, mint, grapefruit, cherry, peach, raspberry, orange, lemon, lime, advantame, etc., or mixtures thereof. Syrups such as cinnamon, orange, citric acid, cherry, cocoa, wild cherry, raspberry, or licorice elixir, raspberry, and other fruit syrups can be used to effectively mask the salty and bitter tastes of many medicines. Metallic tastes (such as iron) in oral liquid products are often masked by extracts of the tropical fruit guarana, but can also be masked by other extracts and drugs.

[0061] The term "sweetener" and its variations generally refer to a solid or liquid ingredient used to impart sweetness to foods or preparations. Sweeteners are often classified as either nutritive (caloric) or non-nutritive (non-caloric), natural or synthetic. Examples of sweeteners include sucrose, dextrose, lactose, glucose, advantame, sorbitol, mannitol, liquid glucose, honey molasses, saccharin, sucralose, rebaudioside A stevia, rebaudioside M stevia, stevioside, mogroside IV, mogroside V, alitame, saccharin, neohesperidin dihydrochalcone, cyclamate, neotame, N-[3-(3-hydroxy-4-methoxybenzyl)propyl]-L-α-aspartyl ]-L-phenylalanine 1-methyl ester, N-[3-(3-hydroxy-4-methoxyphenyl)-3-methylbutanyl]-L-α-aspartyl]-L-phenylalanine 1-methyl ester, N-[3-(3-methoxy-4-hydroxyphenyl)propyl]-L-α-aspartyl]-L-phenylalanine 1-methyl ester, curculin, cyclamate, aspartame, acesulfame potassium, and the like, or mixtures thereof.

[0062] The term "colorant" and variations thereof generally refer to any dye, pigment, or other substance produced by synthetic or similar techniques, or extracted, isolated, or otherwise derived from a plant, animal, mineral, or other source, with or without intermediate or final change in identity, that, when added or applied, can impart color to a food, drug, or cosmetic product or to the human body. Color makes a product attractive, desirable, appetizing, or informative. Examples of colorants include, but are not limited to, brilliant blue FCF, indigotine, alphazurine FG, indigo, indanthrene blue, resorcinol brown, fast green FCF, alizarin cyanine green F, quinizarin green SS, pyranine, dibromofluorescein, diiodofluorescein, erythrosine yellowish sodium, copper phthalocyanine, erythrosine, ponceau SX, lithol rubin B, lithol rubin B. Ca, Tony Red, tetrabromofluorescein, eosin, tetrachlorotetra-bromofluorescein, yellow iron oxide, ultramarine blue, zinc ferrite, chromium oxide green, titanium dioxide, zinc oxide, phloxine, Herringdon Pink CN, Brilliant Lake Red R, Acid Fuchsin, Lake Bordeaux B, Flaming Red, Alba Red, Allura Red AC, Alizarin Purple SS, Alizarin Violet, tartrazine, Sunset Yellow FCF, fluorescein, naphthol yellow S, uranine, quinoline yellow WS, quinoline yellow SS, and others or mixtures thereof.

[0063] The term "permeation enhancer" and its variants generally refer to compounds added to formulations with target drugs to improve the penetration of the active agent through biological membranes such as the skin, nasal, oral, and intestinal mucosa. Examples include, but are not limited to, bile salts, benzene derivatives, fatty acids and derivatives such as oleic acid and lauric acid, glycerides such as phospholipids and medium-chain glycerides, surfactants such as sodium lauryl sulfate and polysorbates, inclusion complexes such as cyclodextrin derivatives, pH adjusters, chelating agents such as disodium ethylenediaminetetraacetate, D-α-tocopheryl polyethylene glycol succinate (TPGS), and mucoadhesive excipients such as chitosan and polycarbophil.

[0064] The term "permeation co-enhancer" and variations thereof generally refers to an excipient that is used to enhance the effect of a permeation enhancer, thus improving the permeation of an API by reducing the lag time between administration of the permeation enhancer and permeation enhancement. Examples include, but are not limited to, polyethylene glycol, propylene glycol, and glycerol.

[0065] "Surface pH" is the pH measured at the surface of a film, such as the top or bottom surface of a monolayer film, or the exposed surface of a layer containing an active agent in a multilayer oral film. The film is prepared for pH testing by slightly wetting the film (adding, e.g., 1-3 drops of water as needed for the pH test). The pH is then measured by contacting an electrode with the surface of the oral film. This surface pH measurement is preferably performed on multiple films of the same formulation.

[0066] The terms "blend" or "blend medium" and variations thereof generally refer to the combination of an oral film dosage with the presence of a solvent.

[0067] As used herein, the term "drug absorption" or "absorption" refers to the process of movement of a drug from a site of administration into the systemic circulation, e.g., the bloodstream of a subject.

[0068] As used herein, the term "dwell time" refers to the time it takes for the film to disintegrate under the tongue or on the buccal mucosa.

[0069] Preferred film dosage forms include sublingual and buccal oral dosage forms. Buccal and / or sublingual mucosal absorption allows drugs to bypass hepatic metabolism and be absorbed directly into the bloodstream. From a pharmaceutical formulation perspective, this is particularly challenging because the process of transmucosal penetration must be carefully optimized to achieve an acceptable pharmacokinetic profile. The use of sustained-release oral films, in which the dissolving film allows the active agent to be delivered directly through the mucosa into the bloodstream, may be desirable to improve the absorption profile of the API and, consequently, its bioavailability.

[0070] Buccal or sublingual film dosage forms may include a single film layer or multiple layers. In some embodiments, bilayer or multilayer films include a mucoadhesive layer containing the API, which is placed on the oral mucosa, and a second layer facing away from the mucosa, which acts as a protective barrier against abrasions from the tongue or chewing, or simply against constant washing with saliva. This protective layer also serves to promote direct absorption of the API in the oral cavity rather than intestinal absorption in the gastrointestinal (GI) tract.

[0071] As used herein, the term "animal" is meant to refer to mammals and excludes humans.

[0072] The present disclosure provides methods and products for topically administering one or more active agents by adhering a film to a mucous membrane, such as the mucous membrane contained in the oral cavity of a human or non-human mammal. A dissolving film containing the active agent is placed on the mucous membrane, such as the membrane in the oral cavity. The hydrophilic nature of the dissolving film causes the film to adhere to the mucous membrane.

[0073] To increase acceptability of the delivery systems of the present disclosure to animal subjects, certain embodiments include flavors such as, but not limited to, beef, chicken, liver, bacon, cheese, apple, smoke, fish, mints such as spearmint or peppermint, and combinations thereof.

[0074] Maropitant is a substituted quinuclidine in the diphenylmethane organic compound family, with the chemical name (2S,3S)-(diphenylmethyl)-N-[2-methoxy-5-(2-methyl-2-propanyl)benzyl]quinuclidine-3-amine and the systematic (IUPAC) name (2S,3S)-N-(5-tert-butyl-2-methoxybenzyl)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octan-3-amine. It is a neurokinin (NK1) receptor antagonist that inhibits the pharmacological action of substance P in the central nervous system (CNS). Maropitant is used to prevent and treat emesis in animals.

[0075] Maropitant also has mild analgesic, anxiolytic, and anti-inflammatory effects. Maropitant and similar classes of compounds can be used pharmaceuticals as antiemetics, autonomic agents, benzene derivatives, central nervous system agents, gastrointestinal agents, and peripheral nervous system agents.

[0076] For injectable dosage forms, users (pet owners) or patients (pets) must receive professional medical and veterinary care for medication administration. At the same time, injectable dosage forms are not the most preferred method due to pain and local irritation, especially for chronic treatments that require repeated and more frequent administration. The route preferred by users and patients is the oral route, as the gastrointestinal tract provides a larger surface area for absorption. However, new advances in this field pose challenges to drug bioavailability due to several limitations, such as the first-pass mechanism in the liver and gastric degradation of drugs.

[0077] While it is known in the art that increasing API loading in oral dosage forms can increase bioavailability and compensate for a portion of the API lost through metabolism and excretion, this approach can increase the potential risk of toxicity, and the risk-benefit imbalance needs to be addressed.

[0078] Veterinary medicines may require higher dosages depending on the animal's weight, which translates into a larger dose per tablet. Higher dose tablets mean larger tablet dimensions to effectively carry larger amounts of API and excipients.

[0079] Administering tablets to animals is difficult because the animal is likely to try to expel the tablet from its mouth, making adhesion a problem. Often, pet owners crush tablets into small pieces and hide them in their animal's food to mask the unpleasant taste and ensure the entire dose is consumed. Tablets may be broken into small pieces or even crushed as a means of overcoming swallowing difficulty or adhesion, but this is not a suitable solution for many tablet or pill forms. For example, crushing or breaking a tablet or pill form to facilitate ingestion alone or mixed with food may compromise the controlled-release properties, taste-masking properties of the dosage form, or otherwise affect the pharmacokinetic properties of the drug.

[0080] Oral films are an alternative dosage form to tablets and offer several advantages, such as a faster onset of action and improved drug bioavailability. However, the limited size, weight, and thickness of the film make it difficult to load a larger amount of drug. Larger films may not fit into the animal's mouth, and thicker films may result in unacceptable disintegration times and mouthfeel, all of which have led tablets back to square one.

[0081] The use of mucoadhesive matrices improves ease of administration and compliance by creating intimate contact with the absorption site, increasing the likelihood of effective penetration and reducing the risk of the animal expelling the dosage form. However, anionic mucoadhesive excipients are incompatible with cationic drugs due to the risk of ionic complex formation, leading to formulation failure. On the other hand, cationic mucoadhesive excipients require a more acidic microenvironment for solubilization, which can be irritating to the buccal mucosa and is neutralized by the pH of saliva. The use of nonionic polymers with improved wettability aids adhesion through hydration and the formation of hydrogen bonds between the polymer's functional groups and the mucosal layer.

[0082] Providing an oral film with a suspended API has the advantage of reducing drug recrystallization, but the short residence time and limited saliva volume for solubilization can slow the rate of API solubilization and drug absorption. Combining the suspension and solubilization approaches allows for a dual system: the suspended API provides slower drug absorption (amorphous molecules are generally more absorbable than crystalline forms), while the solubilized portion enhances the system, covering the initial portion of the drug and enhancing permeability; the remaining suspended API and / or solubilized portion facilitates continued API absorption in the buccal region and / or even the gastric tract.

[0083] Oral films containing solubilized APIs deliver the active agent more rapidly, thereby increasing buccal and / or gastric absorption, but at the risk of API recrystallization. To prevent such instability, the choice of excipients is crucial. However, in some embodiments, maintaining a soluble API generally requires an API-to-solubilizer ratio of less than 1:1, resulting in large film weights and dimensions.

[0084] The use of organic solvents to solubilize API(s) is known in the art, but the choice of polymer is limited due to the limited solubility of the film-forming polymer. For safety reasons (ICH guidelines), a higher percentage of solvent cannot be maintained after the film dries, so the API is prone to recrystallization after drying.

[0085] For high API loading, higher proportions of crystal inhibitors such as polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyvinylpyrrolidone / vinyl acetate (PVP / VA), and poly(vinyl acetate) (PVAc) are required, resulting in a higher percentage of solids in the film formulation.

[0086] Another alternative to volatile solubilizer(s) for the API is nonvolatile solubilizer(s) that remain in the film after the drying step. However, in addition to increasing the solids percentage, such solubilizer(s) are typically liquids with more lipophilic properties. As a result, in the absence of a penetration co-enhancer, the formulation experiences slower drug dissolution and reduced API permeation. The use of liquid solubilizer(s), such as fatty acids, oils, or other lipid-based solubilizer(s), can produce films that are physically unstable, have an oily appearance, long disintegration times, drug precipitation, phase separation of the film mixture, and poor permeation profiles. To mitigate the poor permeation issues, a penetration co-enhancer may be used.

[0087] During permeation studies using a Franz cell device and a buccal porcine mucosal membrane, a suspended maropitant film prototype prepared in aqueous, neutral pH solution exhibited a long lag time and a poor permeation profile. The in vivo results of the latter film prototype were not completely satisfactory. Faster and longer-lasting absorption extensions were needed.

[0088] Maropitant film prototypes, in which the API was dissolved in an organic solvent, crystallized (due to the high API loading) and did not penetrate the porcine mucosa, even with the addition of a crystal growth inhibitor. Maropitant is a cationic drug with a neutral pH, and precipitates formed in polyacid polymer(s) such as CMC, carbomer, and polycarbophil.

[0089] Films made of chitosan polymer did not disintegrate in aqueous solutions at neutral pH because chitosan is a polycationic biopolymer and can only be protonated in weak organic acid solutions at pHs below its pKa (approximately 6.3–6.5).

[0090] Maropitant oral films made with 10% or more oleic acid exhibited an oily appearance, longer disintegration time at neutral pH, and a long lag time during permeation studies.

[0091] Maropitant oral films made with MCT oil in MEK (methyl ethyl ketone) exhibited an oily appearance and drug crystallization.

[0092] The inventors have discovered that making the entire API in a high-potency film permeable to the buccal mucosa requires the API dissolved in a mucoadhesive matrix with a longer residence time. It has been observed that oral films are needed to further improve bioavailability by increasing the solubility or presence of amorphous API, improving penetration into the buccal mucosa to limit first-pass hepatic passage, and formulating a highly mucoadhesive dosage form to increase contact of the API with the mucosa, thereby enabling improved compliance, alternative administration procedures, and reproducible dosing.

[0093] Further improving the API's solubility increases the API's surface area and places it in an amorphous state, thereby inducing an increased rate and extent of API absorption in the buccal microenvironment and shortening the lag time for drug buccal penetration. Furthermore, when the film is applied to the mucosa, it dissolves upon contact with the moist mucosal surface. Hydration of the pH adjuster(s) and / or other components of the oral film generates a microenvironmental pH, which is predicted by measuring the film's surface pH. This microenvironmental pH favors ionization of the API, forming hydrogen bonds with water molecules and thereby solubilizing the API. The soluble ionizable API is in equilibrium with the soluble nonionic form of the API, which is favorable for absorption through the mucosa. As soon as the soluble nonionic form is consumed by permeation through the mucosa, the equilibrium shifts toward providing a more soluble nonionic form of the API. The favorable microenvironmental pH for a basic API is below its pKa, while for an acidic API, it is above its pKa.

[0094] Furthermore, optimal physical properties, such as physical appearance, fold resistance, tensile strength, and elongation, in the film matrix can help maintain product performance throughout its shelf life, which is important. Therefore, combining a matrix system with an API dissolved in a nonvolatile solubilizer(s) and an API suspended in a polymeric mucoadhesive film matrix allows for the concept of a highly loaded film with optimal permeability, film size, stability, and plasticity. This optimal film possesses a polymer with enhanced wettability, which aids in mucoadhesion through rapid hydration. When applied to the buccal mucosa, the readily dissolved API portion enhances permeability and shortens the permeation lag time, while the suspended and / or remaining dissolved API portion promotes continued absorption through the buccal mucosa and / or gastrointestinal tract.

[0095] The present disclosure provides stable, mucoadhesive, flexible films with improved bioavailability, high dosage, and short penetration lag time.

[0096] Dual systems: solubilization and suspension Film matrices for high-potency APIs are only successful when combining two different approaches: a solubilization system using an emulsion to provide the amorphous API, and a suspension system to provide finely dispersed crystals. If only one system (emulsion or suspension) is used, the film matrix will not capture or achieve the properties desired for high-potency APIs.

[0097] In a preferred embodiment, the active pharmaceutical ingredient (API) is present in the film matrix in two ways: solubilized and suspended, making films of high-potency API feasible and successful. The solubilized API increases the API's surface area and is formulated to release the API in an amorphous form. This provides the best dispersion and fastest onset of absorption while overcoming dissolution rate limitations. This results in the fastest onset of action and improved bioavailability.

[0098] At least one solubilizing agent is used to solubilize the poorly water-soluble API, and the solubilizing agent(s) are preferably non-volatile and are intended to maintain an available amorphous form within the dry film.

[0099] Formulating high-load films solely with solubilized APIs poses significant challenges due to the required amount of solubilizer(s) and optional crystal growth-inhibiting polymer(s), resulting in unacceptable film weight and thickness. Using a suspension-only API approach reduces the solids content in the film because it does not require as much solubilizer(s) and stabilizer(s) as the solubilized prototype (crystal growth-inhibiting polymer). However, a small amount of viscosity-increasing / suspending agent, ranging from 10 to 15 times lower than the amount of API, is required to maintain dispersion stability. Suspension APIs reduce permeability compared to solubilized approaches because API release is dissolution rate-limited, but their increased surface area facilitates drug dispersion and dissolution compared to physical mixtures and pure APIs. The suspension approach prevents or at least mitigates uncontrolled and undesirable API recrystallization in cast oral films, which can produce different drug release profiles and potentially lead to product failure.

[0100] Combining the two approaches, solubilized and suspended API, allows for a reduction in total solids usage and allows for the design of stable oral films containing the solubilized portion of the API. The solubilized API facilitates rapid drug release and permeation near the biological membrane upon contact with the body's biological fluids, while the suspended API provides a continuously concentrated API near the biological membrane, maintaining a concentration gradient from the outer cells to the inner cells and facilitating API absorption.

[0101] The higher the percentage of API in the matrix, the closer the API molecules are to each other, making it easier for the API to nucleate recrystallization. Because there is a limit to the weight per surface area that can be coated, crystal growth inhibitors must be used to prevent this, but they are only effective to a limited extent and increase the weight of the film.

[0102] To solubilize the API, in this embodiment, a solubilizer / penetration enhancer with a log p of 8 or less is selected. This provides better solubilizing power, following the adage "like dissolves like." This approach allows the use of less than 6 parts of the solubilizer for each part of the poorly water-soluble API. The lipophilicity of the API and solubilizer / penetration enhancer is proportional to their log p; a higher log p would result in a fatty film matrix, impairing the wettability of the film. The selected solubilizer possesses penetration-enhancing properties, which are key to drug absorption. Having penetration-enhancing properties is advantageous because it allows the amount of solids in the film formulation to be reduced.

[0103] Since the solubilizers / penetration enhancers are lipid-based, they have low water solubility, which reduces the wettability and hydration of the film, resulting in a long penetration lag time and thus is unfavorable for drug release. To address these limitations, it is preferable to limit the lipophilicity of the film matrix by not exceeding 5% of the lipophilic solubilizers / penetration enhancers, or to switch the solubilizers / penetration enhancers to water-soluble solubilizers / penetration enhancers with low log p, or to combine both types of solubilizers / penetration enhancers (lipophilic and water-soluble) to enhance the hydration and wettability of the film, and to increase the amount of solubilized API per film when the ratio of combined solubilizers / penetration enhancers is high.

[0104] Furthermore, the addition of a surfactant system and lipophilic solubilizers / penetration enhancers that meet the required HLB of the API improves the wettability of the film in aqueous media, facilitating drug distribution, film dissolution, drug release, and penetration.

[0105] Additionally, suspending agents (also called "viscosity-enhancing agents") are added to prevent adjacent suspended particles from coming close enough to bond with each other and promote recrystallization. Sufficient increases in the viscosity of the drug vehicle (polymer matrix) allow for steric stabilization of the dispersed drug. In addition to preventing drug crystallization, suspending agents thicken and stabilize emulsions containing the API by increasing viscosity. Furthermore, these suspending agents interact with biological mucosa to create and strengthen mucoadhesion of the oral film, thereby increasing drug penetration and maintaining the API in close proximity to the absorption site.

[0106] To aid in the penetration of APIs and reduce the lag time caused by lipophilic solubilizers / penetration enhancers, penetration co-enhancers are used to increase the aqueous solubility of the solubilizers / penetration enhancers, which allows them to more easily leave the vehicle and increase membrane fluidity, increasing the potential for drug penetration.

[0107] After the active pharmaceutical phase (API, surfactant(s) system, penetration co-enhancer, and solubilizer(s) including suspending / viscosity-enhancing agents) is prepared, a low viscosity polymer with solubility-enhancing properties is added to the mixture with said phase to aid in the incorporation of the organic API into the aqueous system, thereby preventing further precipitation of the API in the dry film.

[0108] To flavor the film, flavorants, flavor enhancers, and sweetener(s) are mixed with the wet blend to create an acceptable flavor profile upon final drying, improve film palatability, mask or eliminate potential aftertastes, as well as intensify sweetness, extend sweetness, and enhance other flavors.

[0109] During the final step of the mixing process, polymer(s) that form the film-forming matrix are added, at least one of which has rapid wettability to form a mucoadhesive matrix with the other, which prevents the growth of API crystals in the final dry film.

[0110] The present disclosure relates to providing a film-forming matrix that carries a high load of drug substance, with a significant portion intended to be released and absorbed via the oral cavity to bypass first-pass hepatic passage, thereby improving the bioavailability of the API.

[0111] In one embodiment, the film-forming matrix contains the API (amorphous) dissolved and suspended using a solubilizer with an appropriate Log P (log p ≤ 8) in an API to solubilizer ratio ranging from 10:3 to 10:60 to enhance loading and maintain a low film weight.

[0112] High-load films contain a portion of the API solubilized, representing more than one-tenth of the total dose, which is maintained in an amorphous form within a surfactant system that helps prevent the API from solubilizing and dispersing. The other portion of the API is suspended to create a film-forming matrix of acceptable weight and dimensions. The concept is to deliver and release the uncharged, highly dispersible, soluble API (amorphous) near the absorption site in the biological mucosa, resulting in an early onset of action that is then maintained by the release and absorption of the API from the suspended portion of the API.

[0113] In a preferred embodiment, the film-forming matrix contains the API dissolved (amorphous) and the API suspended using a solubilizer with an appropriate Log P (log p ≤ 8) in an API to solubilizer ratio ranging from 1:1 to 1:2.5 to enhance loading and keep the film weight low.

[0114] A preferred embodiment also includes the presence of a lipophilic solubilizer / penetration enhancer that helps to carry the amorphous form of the API into the film, which is more soluble than the crystalline form of the API, thereby increasing the hydration and wettability of the film.

[0115] Preferred embodiments also include API suspended under conditions that may allow for solubilization to further enhance oral absorption.

[0116] Preferred embodiments include a penetration enhancer that helps pretreat the mucosal cell membranes to increase membrane fluidity, providing an initial, continuous supply of amorphous API, which is more soluble than crystalline API, a mucoadhesive polymer that helps maintain intimate contact between the film and the biological mucosa for an acceptable period of time, a suspending agent to prevent adjacent suspended particles from coming into close enough proximity to each other to promote recrystallization, and a solubility enhancer to solubilize the API and prevent its recrystallization.

[0117] The concept here is to accelerate the onset of action by enabling early release of the amorphous API from a mucoadhesive, film-forming matrix. The API dissolves readily upon exposure to biological fluids and is introduced into the oral film in close proximity to the buccal mucosa, where increased membrane fluidity facilitates permeation. The matrix prevents crystallization, has highly dispersible particles, and the film-forming polymer favors residence time at the buccal site, increasing the likelihood of higher drug bioavailability. The oral film provides the API at a high loading to accommodate weight gain and maintain a concentration gradient to facilitate drug absorption. The high-potency oral film has a second API portion provided as a suspended API to back up continuity of drug release and, therefore, drug action.

[0118] Generally, oral film dosage forms include a solubilized API in a solubilizer, a permeation co-enhancer, a suspended API, a surfactant system, a suspending agent / viscosity enhancer, and a polymeric film matrix.

[0119] Generally, oral film dosage forms include a solubilized API in a solubilizer, a penetration enhancer, a penetration co-enhancer, a suspended API, a surfactant system, a suspending agent / viscosity enhancer, a plasticizer, a flavor system, chemical stabilizers, and a polymeric film matrix.

[0120] In certain embodiments, the oral film dosage form includes a high-potency API, a solubilizer, a permeation co-enhancer, a suspending / viscosity-enhancing agent, a mucoadhesive film-forming polymer, an amphiphilic solubility enhancer, an anti-aggregation agent, and a surfactant, wherein the solubilized portion of the API is solubilized and less than the remaining suspended portion, and the total API content per film is at least 50 mg and accounts for at least 22% of the total dry weight of the oral film.

[0121] According to some embodiments of the present disclosure, the oral film dosage form comprises at least one API in a dual system: the API in solubilizer(s) and the API suspended in a polymeric mucoadhesive film matrix.

[0122] According to some embodiments of the present disclosure, the solubilized API comprises more than one-tenth of the total dose.

[0123] According to some aspects of the present disclosure, the multi-layer oral film made in part of maropitant or a salt thereof is made in a separate film layer from the maropitant or a salt thereof that is solubilized and suspended.

[0124] According to some embodiments of the present disclosure, the oral film dosage form comprises a solubilizer present in an amount of at least 4% and no more than 30% of the total composition of the oral film.

[0125] According to some embodiments of the present disclosure, the solubilizer is lipid-based, is present in an amount of up to 10% of the total composition of the oral film dosage form, and is composed of one or more fatty acids, derivatives thereof, or combinations thereof, preferably oleic acid or caprylic acid.

[0126] According to some embodiments of the present disclosure, the solubilizer is lipid-based, preferably consisting of one or a combination of oleic acid derivatives or caprylic acid derivatives.

[0127] According to some embodiments of the present disclosure, the solubilizer is a benzene derivative, present in an amount of up to 25% of the total composition of the oral film dosage form, preferably benzyl alcohol or benzyl acetate.

[0128] According to some embodiments of the present disclosure, the solubilizer has a log p of 8 or less.

[0129] According to some embodiments of the present disclosure, the oral film dosage form comprises an API solubilized within a solubilizer system.

[0130] According to some embodiments of the present disclosure, the oral film dosage form comprises an API solubilized in a solubilizer system, the solubilizer system including at least one solubilizer.

[0131] According to some aspects of the present disclosure, the oral film dosage form preferably comprises a solubilizer system comprising a solubilizer with permeation-enhancing properties.

[0132] According to some embodiments of the present disclosure, the ratio of solubilized API to solubilizer(s) is 10:3 to 10:60. According to some embodiments of the present disclosure, the solubilized API in the solubilizer system is made from the following combination: 10 parts lipid-based solubilizer(s) and up to 13 parts benzene-derivative solubilizer(s).

[0133] According to some embodiments of the present disclosure, the solubilized API in the solubilizer system is made from the following combination: 1 part hydrophilic surfactant(s) and up to 4 parts benzene derivative solubilizer(s).

[0134] According to some embodiments of the present disclosure, the solubilized API in the solubilizer system is made from the following combination: 10-12 parts lipid-based solubilizer(s) and 5-15 parts benzene derivative.

[0135] According to some embodiments of the present disclosure, the solubilized API in the solubilizer system is made from the following combination: 10 parts lipid-based solubilizer(s) and up to 15 parts non-volatile solubilizer with pH adjusting functionality.

[0136] According to some embodiments of the present disclosure, the solubilized API in the solubilizer system is made from the following combination: 10 parts lipid-based solubilizer(s), up to 12 parts non-volatile solubilizer(s) with pH adjusting functionality, and up to 6 parts hydrophilic surfactant(s).

[0137] According to some embodiments of the present disclosure, the solubilized API in the solubilizer system is made from the following combination: 5 parts lipid-based solubilizer(s), and up to 7 parts benzene derivative, and up to 8 parts non-volatile solubilizer with pH adjusting function.

[0138] According to some embodiments of the present disclosure, the oral film dosage form includes a water-soluble API.

[0139] According to some embodiments of the present disclosure, the oral film dosage form includes at least one API that does not have an ionizable group.

[0140] According to some embodiments of the present disclosure, the oral film dosage form includes at least one API having at least one ionizable group.

[0141] According to some embodiments of the present disclosure, the oral film dosage form includes an API with acidic properties, such as aspirin or ascorbic acid.

[0142] According to some embodiments of the present disclosure, the API is an API with basic properties, such as, but not limited to, loxapine, maropitant, dimethyltryptamine (DMT), or rizatriptan.

[0143] According to some embodiments of the present disclosure, the oral film dosage form has at least one API with amphoteric properties, such as diclofenac.

[0144] According to some embodiments of the present disclosure, the oral film comprises at least one pH adjusting agent.

[0145] According to some embodiments of the present disclosure, the oral film has a non-volatile solubilizer with pH adjusting functionality of 15% or less of the total dry weight of the oral film.

[0146] According to some embodiments of the present disclosure, the pH adjusting agent(s) create a favorable pH for API solubilization and keep a portion of the drug un-ionized.

[0147] According to some embodiments of the present disclosure, the pH adjuster is HCl, succinic acid, citric acid, sodium hydroxide, sodium citrate, sodium benzoate, or a combination thereof.

[0148] According to some embodiments of the present disclosure, the pH adjusting agent(s) comprise a buffer system consisting of citric acid / sodium citrate or benzoic acid / sodium benzoate, or a combination thereof.

[0149] According to some embodiments of the present disclosure, preferred pH adjusters are selected from the group of inorganic acids, such as, but not limited to, hydrochloric acid, organic acids, such as, but not limited to, citric acid, sodium citrate, succinic acid, and sodium succinate, derivatives thereof, or combinations thereof.

[0150] According to some embodiments of the present disclosure, the pH adjusting agent comprises 12% or less of the total dry weight of the oral film.

[0151] According to some embodiments of the present disclosure, the oral film comprises at least one permeation co-enhancer that is 20% or less of the total dry weight of the oral film.

[0152] According to some embodiments of the present disclosure, the penetration co-enhancer is selected from the group of PEG 300, PEG 400, glycerol, propylene glycol, derivatives thereof, or combinations thereof, preferably polyethylene glycol 300.

[0153] According to some embodiments of the present disclosure, the permeation co-enhancer is 10% or less of the total dry weight of the oral film.

[0154] According to some embodiments of the present disclosure, the solubility enhancer is 10% or less of the total dry weight of the oral film.

[0155] According to some embodiments of the present disclosure, the solubility enhancer is amphiphilic and is selected from the group of HPC SSL and poloxamer, derivatives thereof, or combinations thereof.

[0156] According to some embodiments of the present disclosure, the solubility enhancer is non-amphiphilic and is selected from the group of PEG, PEG derivatives, medium chain triglycerides, glyceride derivatives, or combinations thereof.

[0157] According to some aspects of the present disclosure, the solubility enhancer is preferably hydroxypropyl cellulose SSL.

[0158] According to some embodiments of the present disclosure, the solubility enhancer is 6% or less of the total dry weight of the oral film.

[0159] According to some embodiments of the present invention, the surfactant system is 14% or less of the total dry weight of the oral film and is composed of ingredients selected from, but not limited to, polysorbates, Labrafil M2125CS, Labrasol, propylene glycol monocaprylate type I, propylene glycol monocaprylate type II, lecithin, hydroxylated lecithin, lecithin derivatives, and Gelucire 44 / 14, derivatives thereof, or combinations thereof.

[0160] According to some embodiments of the present disclosure, the surfactant system is preferably a combination of low HLB surfactant(s) (HLB up to 12), such as Labrafil M2125CS, and high HLB surfactant(s) (HLB 12 or greater), such as Polysorbate 20.

[0161] According to some aspects of the present disclosure, the surfactant system preferably includes one surfactant such as lecithin, hydroxylated lecithin, or a lecithin derivative.

[0162] According to some embodiments of the present disclosure, the surfactant system is preferably a combination of 8-9 parts lecithin derivative and 1-2 parts surfactant(s).

[0163] According to some embodiments of the present disclosure, the surfactant system is 15% or less of the total dry weight of the oral film.

[0164] According to some aspects of the present disclosure, the surfactant system preferably comprises no more than 11% of the total dry weight of the oral film.

[0165] According to some aspects of the present disclosure, a non-ionic polymer is formulated with a basic API.

[0166] According to some embodiments of the present disclosure, an anionic polymer is formulated with an acidic API selected from the group of cmc and carbopol for mucoadhesion, but carbopol, like the acidic API, is solubilized at neutral pH.

[0167] According to some embodiments of the present disclosure, the oral film further comprises suspending agent(s) / viscosity increasing agent(s) in an amount of 15% or less, preferably 6% or less, of the total dry weight of the oral film.

[0168] According to some embodiments of the present disclosure, the oral film further comprises 3% or less of suspending agent(s) / viscosity increasing agent(s).

[0169] According to some embodiments of the present disclosure, the suspending agent(s) / viscosity increasing agent(s) are selected from the group of propylene glycol alginate, hydroxypropyl methylcellulose 4000, gellan gum, hydroxyethyl cellulose, guar gum, hydrolyzed guar gum, derivatives thereof, polysaccharide derivatives, cellulose derivatives, or combinations thereof.

[0170] According to some embodiments of the present disclosure, the suspending / viscosifying agent is 11% or less of the total dry weight of the oral film.

[0171] According to some embodiments of the present disclosure, the oral film further comprises at least one plasticizer.

[0172] According to some embodiments of the present disclosure, the plasticizer is no more than 15%, and preferably no more than 10%, of the total dry weight of the oral film.

[0173] According to some embodiments of the present disclosure, the plasticizer is selected from the group of PEG 300, PEG 400, glycerol, propylene glycol, triacetin, preferably polyethylene glycol and / or its derivative(s).

[0174] According to some aspects of the present disclosure, the plasticizer is selected from the group of PEG 300, PEG 400, glycerol, propylene glycol, triacetin, triethyl citrate, derivatives thereof, or combinations thereof.

[0175] According to certain aspects of the present disclosure, the film-forming matrix comprises at least one polymer selected from the group consisting of pullulan, polyvinylpyrrolidone, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, gum arabic, polyacrylic acid, methyl methacrylate copolymer, carboxyvinyl copolymer, starch, gelatin, ethylene oxide-propylene oxide copolymer, collagen, albumin, polyamino acids, polysaccharides, chitin, chitosan, carboxymethylcellulose, derivatives thereof, or combinations thereof.

[0176] According to certain aspects of the present disclosure, the film-forming matrix preferably comprises at least one polymer selected from poly(ethylene oxide), MW 200,000 (PEO 200000), hydroxypropyl cellulose (HPC LF), and hydroxypropyl methylcellulose (HPMC E50).

[0177] According to certain embodiments of the present disclosure, the film-forming matrix comprises no more than 60% of the dry weight of the oral film, and preferably in the range of 25% to 50% of the total dry weight of the oral film.

[0178] According to certain embodiments of the present disclosure, the film-forming matrix preferably comprises 30% to 45% of the total dry weight of the oral film.

[0179] In certain aspects of the present disclosure, the disclosed formulations and excipients are specifically adapted for use in animals.

[0180] In certain aspects of the present disclosure, the disclosed formulations and excipients are particularly adapted for use in animals, particularly for antiemetic treatment.

[0181] In certain aspects of the present disclosure, the disclosed formulations further comprise flavoring(s) to enhance palatability to humans and animals.

[0182] In certain aspects of the present disclosure, the disclosed formulations further comprise flavorings and flavor enhancers to improve human and animal palatability.

[0183] In certain aspects of the present disclosure, the disclosed formulations further comprise flavor(s), flavor enhancer(s), bitter-masking agent(s), and taste-masking agent(s) to enhance human and animal palatability.

[0184] According to some embodiments of the present disclosure, the API delivered by the oral dosage form is maropitant.

[0185] According to some embodiments of the present disclosure, the API delivered by the oral dosage form is maropitant citrate.

[0186] According to some embodiments of the present disclosure, the API delivered by the oral dosage form is a maropitant salt.

[0187] According to some embodiments of the present disclosure, the API delivered by the oral dosage form is ondansetron.

[0188] According to some embodiments of the present disclosure, the API delivered by the oral dosage form is metoclopramide.

[0189] According to some embodiments of the present disclosure, the API delivered by the oral dosage form is dolasetron.

[0190] According to some embodiments of the present disclosure, the API delivered by the oral dosage form is aprepitant.

[0191] According to some embodiments of the present disclosure, the API is delivered with ginger extract for additional antiemetic treatment.

[0192] According to some embodiments of the present disclosure, the oral film contains at least 50 mg of API, which is at least 22% and not more than 70% of the total dry weight of the oral film.

[0193] According to some embodiments of the present disclosure, the surface pH of the oral film ranges from 2.95 to pH 9.0, more preferably a pH that favors maintaining a portion of the drug unionized.

[0194] According to some aspects of the present disclosure, the oral film further comprises a sweetener.

[0195] In certain aspects of the present disclosure, the disclosed formulations further comprise flavor(s), flavor enhancer(s), taste masking agent(s), and sweeteners to enhance human and animal palatability.

[0196] According to some aspects of the present disclosure, the oral film further comprises a colorant.

[0197] In certain embodiments, the orally dissolving film is palatable to humans.

[0198] In certain embodiments, the orally dissolving film is palatable to an animal.

[0199] In certain embodiments, the outer surface of the orally dissolving film has a smooth texture.

[0200] In certain embodiments, the orally dissolving film has high tensile strength.

[0201] In certain embodiments, the orally dissolving film is flexible.

[0202] In certain embodiments, the orally dissolving film is non-sticky to the touch.

[0203] In certain embodiments, the orally dissolving film does not readily stick to another orally dissolving film.

[0204] In certain embodiments, the orally dissolving film is relatively soft to the touch.

[0205] In certain embodiments, the orally dissolving film has a chewable configuration.

[0206] In certain embodiments, the orally dissolving film has an elastic configuration.

[0207] In certain embodiments, the orally dissolving film has an elastic or malleable configuration.

[0208] In certain embodiments, the orally dissolving film has ductile properties.

[0209] In certain embodiments, the orally dissolving film further comprises a bitter taste blocker.

[0210] In certain embodiments, the orally dissolving film further comprises a powder coating present on at least one outer surface of the orally dissolving film.

[0211] In certain embodiments, the orally dissolving film further comprises a powder coating present on two opposing exterior surfaces of the orally dissolving film.

[0212] In certain embodiments, the method of preparing an orally dissolving film is performed in the order shown.

[0213] In certain embodiments, the steps of the method for preparing an orally dissolving film are performed in the order shown.

[0214] In certain embodiments, mixing includes blending.

[0215] In certain embodiments, each of the multiple orally dissolving films of the system is independently at least 2 cm 2 It has dimensions of

[0216] In certain embodiments, each of the multiple orally dissolving films of the system independently has a length of up to 18 cm. 2 It has dimensions of

[0217] In certain embodiments, each of the multiple orally dissolving films of the system is independently 9 cm 2 , with dimensions of ±2.

[0218] In certain embodiments, each of the multiple orally dissolving films of the system is independently 9 cm 2 , with dimensions of ±1.

[0219] In certain embodiments, each of the multiple orally dissolving films of the system independently has a thickness of from about 0.01 mm to about 2 mm.

[0220] In certain embodiments, each of the multiple orally dissolving films of the system independently has a thickness of at least about 0.01 mm.

[0221] In certain embodiments, each of the multiple orally dissolving films of the system independently has a thickness of up to about 2 mm.

[0222] In certain embodiments, each of the multiple orally dissolving films of the system independently has a thickness of from about 0.03 mm to about 1 mm.

[0223] In certain embodiments, some of the excipients used in the orally dissolving films of the present disclosure may have more than one function, and therefore, one of ordinary skill in the art should not construe the excipients described or illustrated in any aspect or embodiment or example of the oral films of the present disclosure as limited to a single function.

[0224] According to some embodiments of the present disclosure, the surfactant system is preferably at least one low HLB surfactant(s) (HLB up to 12).

[0225] According to some aspects of the present disclosure, the surfactant system preferably includes at least one high HLB surfactant(s) (HLB of 12 or greater).

[0226] According to some embodiments of the present disclosure, the surfactant system is preferably a combination of at least one low HLB surfactant(s) (HLB up to 12) and at least one high HLB surfactant(s) (HLB 12 or greater).

[0227] The orally dissolving film of any one of the above embodiments, further comprising a powder coating present on at least one outer surface of the orally dissolving film.

[0228] The orally dissolving film of any one of the above embodiments, further comprising a powder coating present on two opposing exterior surfaces of the orally dissolving film. [Table 1] TIFF2025528791000003.tif242162 [Example]

[0229] Example 1 In this example, a solubilized pharmaceutically active phase is prepared by combining and mixing a portion of the API (in this case, maropitant free base) in a solubilizing system consisting of at least one of fatty acid(s), benzene derivative(s), oil(s), or mixtures thereof to solubilize the API. In parallel, an aqueous phase is prepared by mixing water, penetration enhancer(s), surfactant(s), and co-surfactant(s) to provide the required HLB for the solubilized pharmaceutically active phase or to facilitate emulsification of the solubilized pharmaceutically active phase.

[0230] Both phases (active pharmaceutical phase and aqueous phase) are then combined with mixing, followed by the addition of a viscosity-increasing / suspending agent to stabilize the emulsion. Once the dispersion is formed, an additional amount of API is added to form the suspended API component, and mixing is continued.

[0231] The solubility enhancer(s) are then added, followed by the sweetener(s), flavor enhancer(s), and flavorings.

[0232] Finally, the film-forming polymer(s) are added and mixing is continued until the polymer(s) are completely dissolved. The blend is then degassed and coated at a fixed gap onto a support liner, and finally the coated material is placed in an oven to dry. [Table 2] TIFF2025528791000005.tif213160TIFF2025528791000006.tif45160TIFF2025528791000007.tif253165TIFF2025528791000008.tif244160

[0233] Example 2 In this example, the pharmaceutically active phase includes a solubilizing agent such as, but not limited to, a benzene derivative, such as benzyl alcohol, benzyl acetate, or benzaldehyde. [Table 3]

[0234] Example 3 In this example, the pharmaceutically active phase includes as a solubilizer an oil or mixture of oils, one or a mixture of saturated or unsaturated fatty acids, either esterified or free fatty acids, such as, but not limited to, α-linolenic acid, α-linoleic acid, arachidonic acid, palmitoleic acid, gadoleic acid, caproic acid, heptanoic acid, 11-dodecenoic acid, caprylic acid, ricinoleic acid, and caproleic acid. [Table 4]

[0235] Example 4 In this example, the film-forming matrix contains a pH modifier that aids in solubilizing the API. The pH modifier may be an acid (as shown below for lots 164-24-2, 164-39, 164-33-3, and 164-24-1) or a basic excipient or buffer system that solubilizes all or part of the full strength of the API, resulting in a high surface area for the amorphous form of the API to induce permeability across the oral mucosa.

[0236] As an example of preparing the matrix containing a pH adjuster, the solubilized pharmaceutically active phase is first prepared by solubilizing the entire API under acidic conditions generated by mixing water, an acidifying agent, a plasticizer, a surfactant(s), and a co-surfactant(s) to provide the solubilized pharmaceutically active phase of the required HLB.

[0237] Next, a viscosity increasing / suspending agent is added to stabilize the solution and prevent nucleation, followed by the addition of low viscosity solubilizing polymer(s), followed by the addition of sweetener(s), savor booster(s), and flavor(s).

[0238] Finally, the film-forming polymer(s) are added and mixing is continued until the polymer(s) are completely dissolved. The mixture is degassed and spread into a gap on a support liner, and the spread material is then placed in an oven to dry. [Table 5] TIFF2025528791000012.tif242164TIFF2025528791000013.tif255164TIFF2025528791000014.tif168165

[0239] Example 5 A film-forming matrix that combines a pH-adjusting agent-solubilized API with a solubilizing system made of one of the following: fatty acid(s), benzene derivative(s), oil(s), or a mixture of the above, in which the API is fully solubilized. [Table 6]

[0240] Example 6 In this example, the active pharmaceutical phase uses long chain fatty acids or a large amount of lipid-based excipients or benzene derivatives in the matrix, which causes performance problems (long disintegration time, poor permeability, oily surface). 1 - The pharmaceutically active phase includes two solubilizers, one an organic solvent and the other an oil or mixture of oils, one or a mixture of saturated or unsaturated fatty acids, either esterified or free fatty acids, including but not limited to alpha-linolenic acid, alpha-linoleic acid, arachidonic acid, palmitoleic acid, gadoleic acid, caproic acid, heptanoic acid, 11-dodecenoic acid, caprylic acid, ricinoleic acid, and caproleic acid. 2- The film matrix is ​​free of penetration co-enhancers or has non-functional penetration co-enhancers. 3- Pharmaceutically active phase, where the solubilizer(s) are mostly essential oils such as L-menthone, limonene, eucalyptol, peppermint, etc. 4- The pharmaceutically active phase uses a higher proportion of lipid-based excipients. 5- A film matrix containing 10% or more fatty acid(s) or derivative(s) thereof and 10% or more surfactant(s). 6-Film matrix with 14% or more fatty acid(s). 7- The pharmaceutically active phase uses at least organic solvent(s) to solubilize the API.

[0241] Example 7 In this example, the film-forming matrix of Lot 164-5 A was manufactured under neutral conditions in which a portion of the API was solubilized with oleic acid, emulsified with Labrafil and Tween, and the remaining API (extra) was suspended. Glycerol was used as a penetration enhancer for permeation and as a plasticizer for the film. [Table 7] TIFF2025528791000017.tif99135

[0242] Example 8 In this example, the film-forming matrix of lot 164-5 B was prepared at a pH of approximately 8 to increase the uncharged portion of the API that readily permeates the buccal mucosa. A portion of the API was dissolved in oleic acid and emulsified with Labrafil and Tween, while the remaining API (extra) was suspended. Glycerol was used as a penetration co-enhancer and as a plasticizer for the film. [Table 8] TIFF2025528791000019.tif165152

[0243] Example 9 In this example, film-forming matrices Lot 164-5 C, Lot 164-5 D, and Lot 164-5 B were prepared under neutral conditions, with a portion of the API dissolved in oleic acid and emulsified with Labrafil and Tween, and the remaining API (extra) suspended. Glycerol was used as a penetration co-enhancer for penetration and as a plasticizer for the film. A penetration enhancer was added to each prototype. [Table 9] TIFF2025528791000021.tif235165TIFF2025528791000022.tif135165

[0244] Example 10 In this example, the film-forming matrix of Lot 164-6 A was manufactured under neutral conditions, while Lot 164-6 B was manufactured at a pH of approximately 8 to increase the uncharged portion of the API, which is more susceptible to permeation across the buccal mucosa. Lot 164-6 C was manufactured under neutral conditions with the addition of permeation enhancer(s). For the three films described above, a portion of the API was dissolved in oleic acid and emulsified with Labrafil and poloxamer, while the remaining API (extra) was suspended. Glycerol was used as a permeation co-enhancer and as a plasticizer for the films. [Table 10] TIFF2025528791000024.tif137170

[0245] Example 11 In this example, film-forming matrices for lots 164-6 D and 164-6 E were manufactured under neutral conditions, and permeation enhancers were added to each prototype. In both lots, a portion of the API was dissolved in oleic acid and emulsified with Labrafil and poloxamer, while the remaining API (extra) was suspended. Glycerol was used as a permeation co-enhancer for permeation and as a plasticizer for the film. [Table 11] TIFF2025528791000026.tif223165TIFF2025528791000027.tif48164

[0246] Example 12 In this example, the film-forming matrix of lot 164-13 was manufactured under neutral conditions in which the API was suspended. The primary film-forming polymer was pullulan. [Table 12] TIFF2025528791000029.tif49161

[0247] Example 13 In this example, film-forming matrices for lots 164-15-1 and 164-15-2 were prepared under neutral conditions, and benzyl alcohol was used to solubilize a portion of the API, which was then emulsified with Tween alone (lot 164-15-1) or Labrafil and Tween (lot 164-15-2). The remaining API (extra) was suspended. Glycerol was used as a penetration co-enhancer and as a plasticizer for the film. [Table 13] TIFF2025528791000031.tif163165

[0248] Example 14 In this example, the film-forming matrix for lot 164-16 was manufactured under neutral conditions by dissolving a portion of the API in oleic acid, emulsifying it with Labrafil and Tween, and suspending the remaining API (extras). Glycerol was used as a penetration co-enhancer and as a film plasticizer. The primary film-forming polymer was poly(CMC). [Table 14] TIFF2025528791000033.tif196160

[0249] Example 15 In this example, Lot 164-28-6A and the film-forming matrix of Lot 164-28-6A were manufactured under neutral conditions, with a portion of the API dissolved in oleic acid and emulsified with Labrafil and Tween, and the remaining API (extra) suspended. The total oleic acid was less than 5% dry, and glycerol and propylene glycol were used as penetration co-enhancers for penetration and as plasticizers for the film. [Table 15] TIFF2025528791000035.tif118165

[0250] Example 16 In the following example, a film matrix for Lot 164-Ta was prepared under neutral conditions, in which a portion of the poorly soluble tadalafil was dissolved in propylene glycol monocaprylate, benzyl alcohol, and PEG 300, and then emulsified with Labrafil M2125CS and Tween 20 to suspend the remaining API. PEG 300 was used as a solubilizer, permeation co-enhancer, and plasticizer for the film. [Table 16] TIFF2025528791000037.tif69165

[0251] Example 17 In the following example, the film matrix for Lot 164-Ap was made from a poorly soluble API, apomorphine, which partially dissolved under acidic conditions while the remaining API was suspended. PEG 300 was used as a film solubilizer, permeation co-enhancer, and plasticizer. [Table 17] TIFF2025528791000039.tif66165

[0252] Example 18 In the following examples, the film matrix of Lot 164-Bu was made from a poorly soluble API, in which some of the buprenorphine dissolved in acidic conditions and the remainder was suspended. Propylene glycol was used as a film solubilizer and permeation co-enhancer, as well as a plasticizer. [Table 18] TIFF2025528791000041.tif54165

[0253] In the following example, the film matrix of Lot 164-Vi was made from a water-soluble API in which ascorbic acid was dissolved at neutral conditions. Glycerol was used as a penetration co-enhancer and as a plasticizer for the film. [Table 19] TIFF2025528791000043.tif46165

[0254] Example 19 The film matrix of lot 164-44 is manufactured under neutral conditions, where the API is kept fully suspended with the aid of surfactants and viscosity enhancers, increasing the surface area of ​​the API, but less than that of the solubilized prototype. [Table 20] TIFF2025528791000045.tif33165

[0255] Example 20 In this example, a solubilized pharmaceutically active phase is prepared by solubilizing a combined blend of APIs (DMT) in a solubilizing system consisting of at least one of methanol or ethanol.

[0256] Next, the soluble excipients are added and mixed, followed by the viscosity enhancer / suspending agent / polymer matrix to create the blend.

[0257] The blend is degassed and coated according to a specific gap on the support liner, and finally the coated material is placed in an oven to dry. Due to the size of the film, multiple coating layers may be required to ensure good evaporation of the liquid. [Table 21] TIFF2025528791000047.tif240165TIFF2025528791000048.tif103165

[0258] Manufacturing Procedure: Oral films are produced by dissolving all soluble and / or dispersible ingredients in a selective medium and mixing until all excipients are solubilized and / or dispersed to produce a uniform blend. The active ingredient is then added to the blend and solubilized or dispersed depending on the formulation. The blend is mixed until uniform, after which the polymer is added to the blend and mixed until completely dissolved. Once dissolved and homogenized, the mixing speed is reduced to allow the blend to degas.

[0259] Film products are typically prepared by casting or otherwise spreading a thin film of a liquid film formulation onto a substrate, drying (e.g., evaporating) all or most of the solvent(s) from the film to produce a thin, semi-solid / solid film sheet of material for packaging or processing, and cutting the film sheet into individual unit dosage forms.

[0260] The foregoing description is believed to be of preferred embodiments only. Modifications of these embodiments will occur to those skilled in the art and to those who make or use the illustrated embodiments. It is therefore understood that the above-described embodiments are merely exemplary and are not intended to limit the scope of the present disclosure, which is defined by the following claims as interpreted in accordance with principles of patent law, including the doctrine of equivalents.

Claims

1. 1. An oral film dosage form comprising: i. Suspended maropitant or a salt thereof; ii. an aqueous phase consisting of water and at least one surfactant; iii. at least one viscosity increasing agent / suspending agent; iv. at least one solubilizing agent; The oral film dosage comprising:

2. 10. The oral film dosage of claim 1, wherein the maropitant or a salt thereof is solubilized in a solubilizing system comprising at least one solubilizing agent.

3. The oral film dosage according to claim 2, wherein the ratio of maropitant or its salt to the solubilizing agent is 10:3 to 10:

60.

4. 10. The oral film dosage of claim 1, wherein the maropitant or a salt thereof is solubilized to a maximum of 5%.

5. 10. The oral film dosage of claim 1, wherein the maropitant or a salt thereof is solubilized by up to 40%.

6. 10. The oral film dosage of claim 1, wherein the solubilizer is a benzene derivative selected from the group consisting of benzyl alcohol, benzyl acetate, benzaldehyde, and other benzene derivatives.

7. 10. The oral film dosage of claim 1, wherein the solubilizing agent is a fatty acid selected from the group consisting of α-linolenic acid, α-linoleic acid, arachidonic acid, palmitoleic acid, gadoleic acid, caproic acid, heptanoic acid, 11-dodecenoic acid, caprylic acid, ricinoleic acid, and caproleic acid, other fatty acids, and other fatty acid derivatives.

8. 10. The oral film dosage of claim 1, wherein the solubilizer is selected from the group consisting of a non-volatile excipient, a volatile excipient, and a combination of a volatile excipient and a non-volatile excipient.

9. The oral film dosage of claim 1 , wherein the solubilizer is a surfactant.

10. The oral film dosage of claim 1 , wherein the solubilizer is a solubility enhancer.

11. 10. The oral film dosage of claim 1, wherein the solubilizer comprises an oil, which may be an essential oil.

12. The oral film dosage of claim 1 , wherein the solubilizing agent is a pH adjusting agent.

13. 13. The oral film dosage of claim 12, wherein the pH adjusting agent can be either an acidic excipient, a basic excipient, or a buffer excipient.

14. The oral film dosage according to claim 1, wherein the film surface pH is 9 or less, preferably 8.5 or less.

15. 2. The oral film dosage according to claim 1, wherein the film blend mix pH is 10 or less, preferably 8.5 or less.

16. 1. A method for preparing an oral film, comprising the steps of: a. formulating a film-forming composition, said composition comprising: i. Maropitant or a salt thereof ii. An aqueous phase consisting of water and at least one surfactant iii. comprising at least one viscosity increasing agent / suspending agent; b. solubilizing a portion of maropitant or a salt thereof in a solubilizing system comprising at least one solubilizing agent; c. Preparing an aqueous phase comprising at least one surfactant; d. Mixing the phases; e. adding a second amount of maropitant or its salt; d. adding a viscosity increasing agent / suspending agent to stabilize the emulsion; e. Optionally, adding at least one low viscosity solubilizing polymer; f. optionally adding one or more acceptable excipients selected from the group consisting of co-surfactants, penetration co-enhancers, flavors, flavor enhancers, sweeteners, colorants, plasticizers, stabilizers, antifoaming agents, antioxidants, preservatives, and other excipients; g. adding a film-forming polymer; h. Casting onto a substrate to form a film; i. drying the film to remove the solvent; j. cutting the dried film into individual oral film units; A method comprising:

17. 1. An oral film comprising an API dissolved in a solubilizing agent, a suspended API, a surfactant system, and a viscosity-enhancing agent / suspending agent, wherein a portion of the suspended API exceeds a portion of the API in the solubilizing agent, and wherein the oral film dosage form delivers up to 80 mg of API or 120 mg of an API salt.

18. 20. The oral film of claim 17, further comprising one or more acceptable excipients selected from the group consisting of co-surfactants, penetration co-enhancers, flavorings, flavor enhancers, sweeteners, colorants, plasticizers, stabilizers, antioxidants, antifoaming agents, preservatives, and other excipients.

19. 20. The oral film of claim 17, wherein the solubilizing agent is selected from the group consisting of non-volatile excipients, volatile excipients, and combinations of volatile and non-volatile excipients.

20. The oral film of any one of claims 1 to 19, wherein the oral film is suitable for veterinary use.

Images